ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.-Reference-Cited by-同舟云学术

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:7015-7015
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Seymour John Francis¹,Davids Matthew Steven²,Pagel John M.³,Kahl Brad S.⁴,Wierda William G.⁵,Puvvada Soham⁶,Gerecitano John F.⁷,Kipps Thomas J.⁸,Anderson Mary Ann⁹,Huang David C.S.¹⁰,Rudersdorf Nikita¹¹,Gressick Lori A.¹¹,Montalvo Nicholas P.¹¹,Yang Jianning¹¹,Zhu Ming¹¹,Dunbar Martin¹¹,Cerri Elisa¹¹,Enschede Sari H.¹¹,Humerickhouse Rod¹¹,Roberts Andrew Warwick¹²

Affiliation:

1. Peter MacCallum Cancer Center, Melbourne, Australia

2. Dana-Farber Cancer Institute, Boston, MA

3. University of Washington, Seattle, WA

4. University of Wisconsin Carbone Cancer Center, Madison, WI

5. The University of Texas MD Anderson Cancer Center, Houston, TX

6. University of Arizona, Tuscon, AZ

7. Memorial Sloan-Kettering Cancer Center, New York, NY

8. University of California, San Diego, School of Medicine, San Diego, CA

9. Royal Melbourne Hospital; Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

10. Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

11. AbbVie, Inc., North Chicago, IL